Big Pharma's forays into Big Data worry some security experts; Teva touts its women-in-management record; Actelion's Uptravi grabs Canadian approval;

@FiercePharma: India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat. Story | Follow @FiercePharma

@EricPFierce: #EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. Article | Follow @EricPFierce

@CarlyHFierce: Invokana market share has trended upward post EMPA-REG, $JNJ says. Thank you, $LLY. | Follow @CarlyHFierce

> As a host of top pharma companies--including Novartis ($NVS), Roche ($RHHBY), Novo Nordisk ($NVO) and Sanofi ($SNY)--strike Big Data and cloud-computing deals with tech firms, security experts are worrying about hackers capturing patients' medical information. Report

> Israel-based Teva Pharmaceutical Industries ($TEVA) says almost half of its managers are women, and women occupy 35% of the jobs in it senior executive ranks. Report

> The Swiss-based biotech Actelion won Canadian approval for its new pulmonary arterial hypertension drug Uptravi. Report

> The FDA is scheduled to decide by mid-September whether to approve Amgen's ($AMGN) biosimilar version of AbbVie's ($ABBV) blockbuster Humira. Report

Medical Device News

@FierceMedDev: Theranos flagged by CMS for serious problems at California lab: WSJ. Report | Follow @FierceMedDev

@EmilyWFierce: Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings. FiercePharma article | Follow @EmilyWFierce

> J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations. More

> U.K. startup reels in $45M in JJDC-backed round to boost liquid biopsy ambitions. Article

Biotech News

@FierceBiotech: Amgen's Humira biosimilar nears FDA nod, but legal hurdles remain. Story | Follow @FierceBiotech

@JohnCFierce: So I'll be hanging out at #BIOCEO16 in NYC for a couple of days. Should be fun. | Follow @JohnCFierce

> Codiak piles on more venture cash, amassing $92M for exosome R&D. Story

> With a Duchenne MD patient struggling for life, little Akashi suspends study. More

Pharma Manufacturing News

> Pfizer recalls three lots of top seller Lyrica after production issues. More

> India's Mankind Pharma says it will build a plant in New Jersey. Report

> Inspectors find big issues at API repackager in France. Story

> Teva retrieves amphetamines over impurity concerns. Article

> Sterile injectables manufacturer Sagent said to be shopping itself. More

Pharma Asia News

> Indian firms in a race to buy Nasdaq-listed Sagent, report says. Report

> India and France committed to restart trade talks stalled on GVK row. Story

> Japan's Ono Pharmaceutical gears up sales reps for Opdivo. Item

> China-based VC firm WuXi Healthcare makes coast-to-coast U.S. investments. More

> India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat. Article

Drug Delivery News

> Startup Co-D aims to resuscitate failed BMS drug using polymeric micelle drug delivery. More

> UNC team delivers cancer drugs wrapped in exosomes to cut doses. Report

> Combining light-activated and chemical treatments, new nanoparticles are more effective against tumors. Story

> Endangered inhaled insulin player MannKind collaborates with mysterious 'entity' on R&D. Item

> Cancer-focused Ensysce Biosciences adds opioid prodrug to its pipeline via merger. Article

And Finally... Should doctors use drug therapy to put a damper on painful memories? Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.